AiM Medical Robotics, a Fort Lauderdale, Fla.-based developer of MRI-compatible intraoperative robotics for neurosurgery, raised $3.4m in seed funding.
The round was led by IQ Capital and Surrey Capital Partners with participation from The Lambda Fund, a part of the Lamport Family Office, Triple Ring Technologies, and Worcester Polytechnic Institute (WPI), amongst additional inside investors. As of the close, Samantha Surrey, Founder of Surrey Capital Partners, has joined AiM’s Board of Directors.
The company intends to use the funds to accelerate the development of its MRI-compatible robotics platform, and to continue to grow its team across research, engineering, and clinical and medical affairs.
Led by Bob Cathcart, CEO, AiM is advancing the MRI-compatible robotics platform, which is designed to improve outcomes for patients undergoing neurosurgery for functional brain disorders (Parkinson’s, Epilepsy, etc.) and cancer and provide cost savings to hospitals by eliminating errors and reducing procedure times. The company will also
In March 2022, AiM announced that it had appointed Dr. Jonathan Sackier as its Chief Medical Officer (CMO). The news came on the heels of AiM’s announcement that Gregory Cole, Ph.D. had been appointed as its Chief Technology Officer (CTO).
FinSMEs
15/03/2022